A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab
Objectives: IgG4-related disease (IgG4-RD) is a chronic fibro-inflammatory disorder affecting virtually any organ. Type 1 autoimmune (type 1 AIP) is its pancreatic manifestation. To date, steroids are considered the first-line pancreatitis treatment. The CD20-binding antibody rituximab (RTX) appears...
Main Authors: | Johanna Backhus, Christian Neumann, Lukas Perkhofer, Lucas A Schulte, Benjamin Mayer, Thomas Seufferlein, Martin Müller, Alexander Kleger |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/6/1329 |
Similar Items
-
Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022-12-01) -
IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease
by: Rodrigo V. Motta, et al.
Published: (2024-02-01) -
Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report
by: Denis T. Balaban, et al.
Published: (2023-05-01) -
Anti-NF155/NF186 IgG4 Antibody Positive Autoimmune Nodopathy
by: Lijun Wang, et al.
Published: (2022-11-01) -
Features of the course of diabetes mellitus in IgG4-associated disease
by: T. S. Panevin, et al.
Published: (2023-08-01)